What does the collaboration establish, and which payments remain potential?
- Sino Biopharm and Boehringer Ingelheim signed an oncology project option and license agreement covering 6 preclinical programs in areas including antibody-drug conjugates (ADCs) and T-cell engagers. 5 programs are from subsidiary LaNova Medicines, while 1 is from Beijing Tide. This is the parties’ second oncology collaboration.
- Under the agreement, Sino Biopharm is entitled to 358 million in upfront and near-term payments, although the report did not disclose the breakdown between the two. There are also potential option-exercise, development, regulatory and commercial milestone payments of up to 7 billion, as well as royalties of up to a high double-digit percentage on future product sales; these amounts are not confirmed revenue.
How will the parties share development, and when do the licensed rights take effect?
- Sino Biopharm is responsible for early-stage development through completion of global Phase I clinical trials. Boehringer Ingelheim may exercise the project options only after the clinical milestones agreed by both parties have been met.
- After exercising the options, Boehringer Ingelheim will obtain exclusive development, manufacturing and related rights for 4 of the programs outside mainland China, Hong Kong and Macau, while global rights will be granted for the other 2. The rights arrangement is linked to exercise of the options; all rights are not transferred upon signing.
How does the transaction change BofA’s financial forecasts?
- BofA raised its 2027 revenue forecast from RMB 40.53 billion to 42.531 billion, an increase of 4.9%. Its 2028 forecast rose from 44.008 billion to 44.395 billion, an increase of 0.9%. Its forecasts for net profit attributable to shareholders of the parent were raised by 15.3% and 2.7%, respectively.
- The model includes only the 358 million in upfront and near-term payments, most of which is expected to be recognized in 2027. Potential option and milestone payments of up to 7 billion are not included as confirmed revenue. The forecast increase is therefore concentrated in the agreed near-term payments and does not mean that the full potential value of the collaboration has been included in earnings.
Why did BofA raise its target price, and what constraints apply to its assessment?
- BofA believes the collaboration further validates Sino Biopharm’s next-generation oncology platform, particularly the programs at LaNova Medicines, and supports its expansion of international partnerships. On this basis, it slightly raised its DCF target price from HK$7.4 per share to HK$7.5, while maintaining its Buy rating.
- The path to realizing the value still spans clinical development, exercise of the options by Boehringer Ingelheim, and subsequent development and commercialization; all 6 programs are currently preclinical. BofA therefore includes only 358 million in its model, while the value of potential milestone payments and royalties depends on subsequent progress.